Stellantis takes massive hit for 'overestimation' of EV shift

Weather - Sydney 9°C

Stellantis takes massive hit for 'overestimation' of EV shift

ECONOMY 06.02.2026

Stellantis takes massive hit for 'overestimation' of EV shift / Photo: © AFP

Jeep maker Stellantis warned Friday that it would take a 22 billion euro hit after a slower takeup of electric vehicles than it expected, the latest sign that legacy automakers are struggling to navigate the shift away from combustion engines.

Change text size:

The admission of a "significant overestimation" of demand for EVs comes as authorities in the US and Europe have eased strict emissions targets after years of demanding cleaner vehicles.

US auto giants Ford and General Motors also recently announced multibillion-dollar write-downs as they pull back on EV operations, sparked in large part by President Donald Trump's scrapping of hefty US subsidies for electric cars.

But the colossal $26 billion write-down at Stellantis also comes after months of management turmoil that saw the ousting of former chief Carlos Tavares in late 2024 over his contested premium pricing policy.

He was replaced in July by Antonio Filosa, an Italian and Fiat veteran who immediately embarked on a management shake-up and a vow to restore profitability after a 70 percent plunge in 2024 net profit to 5.5 billion euros.

But Filosa has not stopped the erosion of Stellantis's stock price, which plunged nearly 23 percent Friday to 6.32 euros -- and has lost roughly three-fourths of its value since March 2024.

"The charges announced today largely reflect the cost of over-estimating the pace of the energy transition that distanced us from many car buyers' real-world needs, means and desires," Filosa said in a statement.

"They also reflect the impact of previous poor operational execution, the effects of which are being progressively addressed by our new team," he said.

Filosa will host a conference call with investors at 2:00 pm (1300 GMT) on Friday.

- 'Freedom of choice' -

Stellantis, whose 14 brands also include Fiat and Peugeot as well as Ram trucks, Dodge, Chrysler and Maserati, has been slammed in particular by falling sales in its key North American market.

It was born of the 2021 merger of France's PSA with its US-Italian rival Fiat Chrysler, creating the world's fourth-biggest automaker.

"Even though a 'reset' was widely expected... the scope of today's announcements are beyond even the most cautious expectations," said analysts at investment bank Oddo BhF said, adding they had anticipated a 7 billion euro write-down.

In its statement, Stellantis said reducing its EV focus would offer clients "freedom of choice, including for those customers whose lifestyles and working requirements make the company's growing range of hybrid and advanced internal combustion engine vehicles the right solution".

As recently as October it announced plans to invest $13 billion in US plants over the next four years, widely seen as a response to Trump's tariffs on imported autos and parts.

Later that month it posted a 13 percent rise in third-quarter revenues, citing improved business in the United States.

"We have gone deep into every corner of our business and are making the necessary changes, mobilising all the passion and ingenuity we have within Stellantis," Filosa said in the statement.

B.Cooper--TNT

Featured

Nearly 1,100 flights cancelled after UK air traffic control glitch

Almost 1,100 flights to and from UK airports were cancelled Tuesday due to what the country's air traffic control service called a technical issue, in the latest glitch to spark travel chaos.

Carney touts Canada 'pivot' away from US as tariffs rise

Canadian Prime Minister Mark Carney on Tuesday said reducing economic ties with the United States would come at a cost but the long-term benefits were clear, as retaliatory tariffs on US products took effect.

The "Everlasting Battery" Inside Your Joints:UConn Professor's Self-Powered Healing Material just Got Acquired

A material that turns your own movement into medicine has just landed a corporate home. PetVivo Holdings (OTCQX: PETV), a veterinary biotech and biomedical device company focused on treating osteoarthritis in dogs and horses, has acquired PiezoBioMembrane (PBM) — a startup built around a biodegradable implant that generates electricity from the everyday force of a joint in motion, and uses that charge to help regrow cartilage from the inside out. The material is the invention of Thanh Nguyen, a professor of mechanical engineering in UConn's College of Engineering, who founded PBM in 2021 to advance new implementation methods for his work with piezoelectric materials — substances that convert mechanical force into electrical energy. These materials are typically ceramics: hard, brittle, and poorly suited for medical use. But Nguyen's lab developed new forms that are so , flexible, and biodegradable, breaking down naturally within the body over time. wound healing, The materials have already shown strong potential across a range of medical applications, including tissue regeneration, implanted force sensors, and targeted drug delivery in tumor treatment. How It Works biodegradable ultrasound for In the case of arthritis, Nguyen explains, the piezoelectric materials function as an off-the-shelf product that can be implanted or injected directly into the ailing joint — with no drugs, chemicals, or cells required. The everyday force exerted on the joint generates a small electrical charge, which helps regrow healthy cartilage, mimicking the body's natural use of electricity to regenerate tissue. "The body can be electrically stimulated to regrow," Nguyen says. PBM's materials "act like a battery — an everlasting battery that works whenever there is a force applied, and vanishes safely inside the body over time." PetVivo's Vision for the Acquisition PetVivo Holdings CEO John Lai expressed enthusiasm for the merger's potential to improve the lives of companion animals globally. "PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets," Lai said in a press release. "By combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, regulatory expertise, and public company infrastructure, we believe we can accelerate theadvancement of technologies that may serve as the foundation for numerous future products and strategic opportunities." For Nguyen, the deal is a chance to scale technology that could eventually benefit both animals and people. "PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use," Nguyen says. "That aligned perfectly with my passion for developing technology that has an impact on human life. That is why I am excited about this merger, which facilitates my passion." A Track Record of Innovation Nguyen's research sits at the intersection of medicine, micro/nanotechnology, and biomaterials. His inventions have earned him publications in prominent scientific journals and media coverage from outlets including NPR. Nguyen founded PBM during the COVID-19 pandemic, a er realizing the material he had developed could be used to create an especially effective, biodegradable face mask — one where the mechanical force of breathing generated an electrical charge that provided an extra layer of protection against viruses. PBM is not Nguyen's only venture in the acquisition pipeline. His other startup, Single-Time Microneedles (STM), is also currently undergoing an acquisition process. STM has pioneered stable, efficient vaccine delivery technology in the form of an adhesive patch. shelfNguyen's focus on biodegradable materials has translated into a remarkably diverse range of medical applications. He has received five R01 grants from the National Institutes of Health (NIH) supporting research in cartilage regeneration, bone regeneration, HIV antibody delivery systems, and biodegradable ultrasound technology to boost the effectiveness of chemotherapy for brain cancer. "Whatever we are working on, we want to show that it works very well in vitro and in vivo," Nguyen says. "Then, when we are at the point of commercialization, we set up a startup or license the technology — or maybe team up with an industry partner." Thanh Nguyen is a professor of mechanical engineering in UConn's College of Engineering. (Courtesy of Thanh Nguyen

Octrado introduces its proprietary trading offering: "Your Skill. Our Capital"

Infrastructure, transparent rules and clear legal boundaries positioned as the core of the funded-account model

Change text size:

The National Times - Stellantis takes massive hit for 'overestimation' of EV shift